TELA Bio, Inc. (TELA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
TELA Bio, Inc. (TELA) trades at $0.6393 with AI Score 21/100 (Grade F). TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions. Market cap: $28.6M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for TELA: TELA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TELA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TELA: 2/3 scored disciplines lean bearish. Dominant signal: Valuation weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
TELA Bio, Inc. (TELA) Healthcare & Pipeline Overview
TELA Bio, Inc. develops and markets soft-tissue reconstruction solutions, primarily the OviTex Reinforced Tissue Matrix, for hernia repair and reconstructive surgery. The company's focus on preserving patient anatomy and its direct sales force in the United States position it within the competitive medical device landscape.
What Is the Investment Thesis for TELA?
TELA Bio presents a notable research candidate within the medical device sector, driven by its innovative OviTex technology and expanding applications in soft-tissue reconstruction. The company's focus on biologic scaffolds and minimally invasive procedures aligns with current trends in surgical care. A key value driver is the increasing adoption of OviTex in hernia repair and abdominal wall reconstruction, with potential for further market penetration through its plastic and reconstructive surgery products. The company's gross margin of 67.7% indicates strong pricing power and efficient manufacturing processes. However, the company's negative profit margin of -48.4% highlights the need for improved cost management and operational efficiency. Upcoming catalysts include potential regulatory approvals for new OviTex applications and expansion of the sales force to reach a broader customer base. Potential risks include competition from established players in the surgical mesh market and the need for continued innovation to maintain a competitive edge.
Based on FMP financials and quantitative analysis
TELA Key Highlights
Gross Margin of 67.7% demonstrates strong pricing power and efficient manufacturing.
- Focus on biologic scaffolds aligns with the growing trend towards natural and biocompatible materials in surgical procedures.
- Direct sales force in the United States allows for targeted marketing and customer engagement.
- OviTex portfolio addresses a significant market need in hernia repair, abdominal wall reconstruction, and plastic/reconstructive surgery.
- Market capitalization of $28.6M presents potential for growth if the company can achieve profitability and expand its market share.
Who Are TELA's Competitors?
TELA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TELA's Key Strengths?
Proprietary OviTex technology.
- Focus on preserving patient anatomy.
- Direct sales force in the United States.
- Growing portfolio of products for various surgical applications.
What Are TELA's Weaknesses?
Negative profit margin.
- Limited geographic reach (primarily US).
- Reliance on a single product line (OviTex).
- Relatively small market capitalization.
What Could Drive TELA Stock Higher?
Potential regulatory approvals for new OviTex applications.
- Expansion of the sales force to reach a broader customer base.
- Increasing adoption of OviTex in hernia repair and abdominal wall reconstruction.
- Continued product development and innovation in soft-tissue reconstruction.
What Are the Key Risks for TELA?
Financial-distress signal — its Altman Z-Score of -9.45 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from established players in the surgical mesh market.
- Regulatory hurdles for new products and applications.
- Product liability claims.
- Need for continued innovation to maintain a competitive edge.
- Negative profit margin and the need for improved cost management.
What Are the Growth Opportunities for TELA?
- Expansion into Plastic and Reconstructive Surgery: The OviTex PRS Reinforced Tissue Matrix products represent a significant growth opportunity for TELA Bio. The market for reconstructive surgery is estimated to be worth billions of dollars annually, driven by increasing demand for breast reconstruction, body contouring, and facial reconstruction procedures. By targeting this market, TELA Bio can diversify its revenue stream and capitalize on the growing demand for advanced soft-tissue reconstruction solutions. The timeline for this growth opportunity is ongoing, with continued product development and market penetration efforts.
- Geographic Expansion Beyond the United States: Currently, TELA Bio primarily markets its products in the United States. Expanding into international markets, such as Europe and Asia, represents a significant growth opportunity. These markets have large patient populations and increasing demand for advanced surgical technologies. The timeline for this growth opportunity is estimated to be within the next 3-5 years, requiring regulatory approvals and establishment of distribution networks in target countries.
- Development of New OviTex Applications: TELA Bio can further expand its market reach by developing new applications for its OviTex technology. This could include applications in other surgical specialties, such as orthopedic surgery or cardiovascular surgery. The development of new OviTex applications would require further research and development, as well as clinical trials to demonstrate safety and efficacy. The timeline for this growth opportunity is estimated to be within the next 5-7 years.
- Strategic Partnerships and Acquisitions: TELA Bio can accelerate its growth by forming strategic partnerships with other medical device companies or acquiring complementary technologies. This could provide access to new markets, distribution channels, or product portfolios. Potential acquisition targets could include companies with expertise in biologic scaffolds, surgical meshes, or minimally invasive surgical technologies. The timeline for this growth opportunity is ongoing, with potential partnerships and acquisitions being evaluated on a case-by-case basis.
- Increased Adoption of Minimally Invasive Surgical Techniques: The growing trend towards minimally invasive surgical techniques, such as laparoscopic and robotic surgery, presents a significant growth opportunity for TELA Bio. The company's OviTex for Laparoscopic and Robotic Procedures is specifically designed to meet the needs of these procedures. As more surgeons adopt minimally invasive techniques, the demand for OviTex will likely increase. The timeline for this growth opportunity is ongoing, with continued training and education programs to promote the use of OviTex in minimally invasive surgery.
What Are TELA's Competitive Advantages?
- Proprietary OviTex technology combining biologic and synthetic materials.
- Focus on preserving and restoring patient anatomy.
- Direct sales force providing targeted marketing and customer engagement.
What Does TELA Do?
TELA Bio, Inc., incorporated in 2012 and headquartered in Malvern, Pennsylvania, is a commercial-stage medical technology company dedicated to providing innovative soft-tissue reconstruction solutions. The company's core mission revolves around optimizing clinical outcomes by prioritizing the preservation and restoration of the patient's natural anatomy. TELA Bio's primary product is the OviTex Reinforced Tissue Matrix (OviTex), a unique biologic scaffold used in a variety of surgical procedures. OviTex is derived from ovine rumen and reinforced with polypropylene fiber, offering surgeons a strong and biocompatible material for hernia repair and abdominal wall reconstruction. The company has expanded its OviTex portfolio to include OviTex PRS Reinforced Tissue Matrix products, specifically designed to address the unmet needs in plastic and reconstructive surgery. These products offer enhanced handling characteristics and improved aesthetic outcomes. Furthermore, TELA Bio offers OviTex for Laparoscopic and Robotic Procedures, catering to the growing demand for minimally invasive surgical techniques. TELA Bio markets its products through a direct sales force, primarily targeting surgeons in the United States. The company's focus on innovation, clinical outcomes, and direct customer engagement has allowed it to establish a growing presence in the soft-tissue reconstruction market.
What Products and Services Does TELA Offer?
- Develop and market soft-tissue reconstruction solutions.
- Offer the OviTex Reinforced Tissue Matrix for hernia repair.
- Provide OviTex PRS Reinforced Tissue Matrix for plastic and reconstructive surgery.
- Offer OviTex for Laparoscopic and Robotic Procedures.
- Focus on preserving and restoring patient anatomy.
- Market products through a direct sales force in the United States.
How Does TELA Make Money?
- Develop, manufacture, and sell OviTex Reinforced Tissue Matrix products.
- Target surgeons specializing in hernia repair, abdominal wall reconstruction, and plastic/reconstructive surgery.
- Utilize a direct sales force to market and sell products in the United States.
What Industry Does TELA Operate In?
TELA Bio operates within the medical device industry, specifically focusing on soft-tissue reconstruction. The market for hernia repair and abdominal wall reconstruction is substantial and growing, driven by an aging population and increasing rates of obesity. The competitive landscape includes established players offering synthetic meshes and biologic grafts. TELA Bio differentiates itself through its OviTex technology, which combines the benefits of both synthetic and biologic materials. The industry is also characterized by increasing demand for minimally invasive surgical techniques, which TELA Bio addresses with its OviTex for Laparoscopic and Robotic Procedures.
Who Are TELA's Key Customers?
- Surgeons specializing in hernia repair.
- Surgeons specializing in abdominal wall reconstruction.
- Surgeons specializing in plastic and reconstructive surgery.
Company Profile
TELA Bio, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Malvern, US. The company is led by CEO Antony Koblish. TELA has traded publicly since 2019.
TELA Bio, Inc. Financial Trajectory
TELA Bio, Inc. (TELA) reported $19.3M in revenue for Q2 2026, reflecting 1.2% growth compared to the prior quarter. The company recorded a net loss of $11.3M, with diluted EPS of $-0.20. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, TELA averaged $-0.19 in diluted EPS.
How TELA Bio, Inc. Is Valued
TELA Bio, Inc. carries a market capitalization of $28.6M, placing it in the micro-cap category. Relative to its peer group, TELA's quantitative score of 21/100 is below the peer average of 65/100.
Key Financial Metrics
Return on assets is -68.9%, showing how much profit it generates from its asset base. A current ratio of 2.99 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -111.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
TELA Bio, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.45 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
TELA Bio, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 14.5% below estimates on average.
Forward Outlook
Wall Street analysts project TELA Bio, Inc. revenue of about $86.7M for fiscal 2026, with EPS near $-0.65. The estimate reflects 3 contributing analysts.
TELA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- TELA Bio's recent insider buying suggests those in the know are optimistic about the company's prospects. It's like when Musk was buying up Tesla shares – a strong signal.
- The buzz in the social trading community is generally positive, with many seeing long-term potential in their regenerative tissue matrix products. Think of it as the early days of CRISPR, lots of excitement.
- There's a growing perception that TELA Bio is addressing a significant unmet need in reconstructive surgery. Similar to how Intuitive Surgical cornered the market with robotic surgery.
- The overall market sentiment seems to be improving, with more investors willing to take on risk in the medical device sector. This rising tide could lift all boats, like the tech boom of the late 90s.
Bear Case
- Despite insider buying, some worry about the company's long-term profitability. It's reminiscent of the early days of many biotech firms – great science, but tough economics.
- A segment of the community feels the company is overvalued compared to its current revenue. This is a common concern with growth stocks, like the dot-com bubble all over again.
- There are concerns that larger players in the medical device space could develop competing products. It's like when Amazon enters a market – everyone gets nervous.
- The broader market is still facing macroeconomic headwinds, which could impact TELA Bio's ability to raise capital or expand. Think of the 2008 financial crisis – even good companies suffered.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $19M | -$11M | -$0.20 |
| Q1 2026 | $19M | -$12M | -$0.21 |
| Q4 2025 | $21M | -$9M | -$0.17 |
| Q3 2025 | $21M | -$9M | -$0.19 |
Based on FMP financials and quantitative analysis
TELA Latest News
-
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga · Jun 25, 2026
TELA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TELA.
Price Targets
Wall Street price target analysis for TELA.
TELA MoonshotScore
What does this score mean?
The MoonshotScore rates TELA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Antony Koblish
CEO
Antony Koblish serves as the Chief Executive Officer of TELA Bio, Inc. His background encompasses extensive experience in the medical device industry, with a focus on commercialization and strategic leadership. Prior to joining TELA Bio, Koblish held various leadership positions at leading medical device companies, where he was responsible for driving revenue growth, developing new markets, and managing product portfolios. He brings a wealth of knowledge in sales, marketing, and business development to TELA Bio.
Track Record: Under Antony Koblish's leadership, TELA Bio has focused on expanding the OviTex portfolio and increasing market penetration in the United States. He has overseen the launch of new products, such as OviTex PRS, and has implemented strategies to improve sales force effectiveness. His focus has been on driving revenue growth and achieving profitability.
TELA Healthcare Stock FAQ
What does the AI Score mean for TELA?
TELA holds an AI Score of 21/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions. Their OviTex portfolio addresses unmet needs in hernia repair, abdominal wall …
What does TELA Bio, Inc. do?
TELA Bio, Inc. is a medical technology company focused on designing, developing, and marketing soft-tissue reconstruction solutions. Their primary product, OviTex Reinforced Tissue Matrix, is used in hernia repair, abdominal wall reconstruction, and plastic/reconstructive surgery. OviTex is a unique biologic scaffold derived from ovine rumen and reinforced with polypropylene fiber, offering surgeons a strong and biocompatible material for these procedures.
What do analysts say about TELA stock?
Analyst coverage of TELA Bio, Inc. is limited, reflecting its small market capitalization and relatively early stage of commercialization. The consensus view is that TELA Bio has the potential for significant revenue growth, driven by its innovative OviTex technology and expanding applications. However, analysts also highlight the risks associated with competition, regulatory hurdles, and the company's current lack of profitability.
What are the main risks for TELA?
TELA Bio faces several risks, including competition from established players in the surgical mesh market, regulatory hurdles for new products and applications, and the potential for product liability claims. The company's negative profit margin and reliance on a single product line (OviTex) also pose significant risks.
How does TELA Bio, Inc. navigate regulatory approval processes?
TELA Bio, Inc. navigates regulatory approval processes primarily through the FDA's 510(k) pathway for medical devices. This pathway requires demonstrating that the company's devices are substantially equivalent to legally marketed predicate devices. The company maintains a focus on compliance with FDA regulations and quality control standards throughout the product development and manufacturing processes.
What are the key growth opportunities for TELA in healthcare?
Key growth opportunities for TELA Bio, Inc. lie in expanding the applications of its OviTex technology within the healthcare sector. This includes increasing market penetration in existing applications such as hernia repair and abdominal wall reconstruction, as well as expanding into new therapeutic areas such as plastic and reconstructive surgery.
What are the key factors to evaluate for TELA?
TELA Bio, Inc. (TELA) holds an AI score of 21/100 (low). TELA Bio presents a notable research candidate within the medical device sector, driven by its innovative OviTex technology and expanding applications in soft-tissue reconstruction. Not financial advice.
How frequently does TELA data refresh on this page?
TELA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TELA's recent stock price performance?
TELA Bio, Inc. (TELA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary OviTex technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on publicly available information and may be subject to change.
- Analyst opinions are based on limited coverage and may not reflect the views of all analysts.
- This dossier is for informational purposes only and does not constitute investment advice.